Adjuvant endocrine therapy in estrogen-low breast cancer in the era of CDKI: are we at another uncertain crossroads?
- DOI
- 10.3389/fonc.2026.1636348
- Published
- 2026
- Container
- Frontiers in oncology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3389/fonc.2026.1636348,
title = {Adjuvant endocrine therapy in estrogen-low breast cancer in the era of CDKI: are we at another uncertain crossroads?},
author = {Valerio MR and Scandurra G and Greco M and Mesi C and Gebbia V and Sambataro D},
year = {2026},
journal = {Frontiers in oncology},
doi = {10.3389/fonc.2026.1636348},
url = {https://doi.org/10.3389/fonc.2026.1636348}
}RIS
TY - JOUR TI - Adjuvant endocrine therapy in estrogen-low breast cancer in the era of CDKI: are we at another uncertain crossroads? AU - Valerio MR AU - Scandurra G AU - Greco M AU - Mesi C AU - Gebbia V AU - Sambataro D PY - 2026 JO - Frontiers in oncology DO - 10.3389/fonc.2026.1636348 UR - https://doi.org/10.3389/fonc.2026.1636348 ER -
APA
MR, V., G, S., M, G., C, M., V, G., & D, S. (2026). Adjuvant endocrine therapy in estrogen-low breast cancer in the era of CDKI: are we at another uncertain crossroads?. Frontiers in oncology. https://doi.org/10.3389/fonc.2026.1636348
Source records
- pubmed · retrieved 2026-11-10T10:13:36.681Z